Stenotrophomonas maltophilia (S. maltophilia) has recently emerged as an important nosocomial pathogen. Treatment of invasive infections caused by this organism is difficult as the bacterium is frequently resistant to a wide range of commonly used antimicrobials. Trimethoprimsulfamethoxazole (TMP - SXT) is recommended as the agent of choice for the treatment of S. maltophilia infections. However, the development of resistance to this antibiotic represents a real challenge to laboratorians and clinicians. This letter describes the first isolation of S. maltophilia resistant to TMP - SXT from two patients treated at Riyadh Armed Forces Hospital which is a major tertiary hospital in Saudi Arabia. © 2006 Al-Jasser; licensee BioMed Central Ltd.
CITATION STYLE
Al-Jasser, A. M. (2006). Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: An increasing problem. Annals of Clinical Microbiology and Antimicrobials, 5. https://doi.org/10.1186/1476-0711-5-23
Mendeley helps you to discover research relevant for your work.